Related Experiment Video

Updated: Jul 6, 2026

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
08:34

Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy

Published on: September 25, 2017

Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway

Juan Liu1, Qin Shen, Yang Wu

  • 1Institute for Nautical Medicine, Nantong University, Nantong, Jiangsu Province 226001, People's Republic of China.

Life Sciences
|April 11, 2008
PubMed

Insights

Simvastatin (SIM) effectively treats cardiac hypertrophy by reducing cardiomyocyte size and improving heart function. This HMG-CoA reductase inhibitor works by influencing the JAK/STAT pathway and angiotensin pathways.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Simvastatin (SIM), a HMG-CoA reductase inhibitor, exhibits therapeutic effects beyond cholesterol reduction.
  • Cardiac hypertrophy is a significant risk factor for heart failure and cardiovascular events.
  • Cardiotrophin-1 (CT-1) is a cytokine implicated in cardiac cell growth and survival, and its dysregulation can contribute to hypertrophy.

Purpose of the Study:

  • To investigate the effects of SIM on CT-1-induced cardiomyocyte hypertrophy in vitro.
  • To evaluate the efficacy of SIM in attenuating cardiac hypertrophy in a rat model of pressure overload.
  • To elucidate the molecular mechanisms underlying SIM's inhibitory effects on cardiac hypertrophy.

Main Methods:

  • In vitro studies using cultured rat cardiomyocytes exposed to CT-1 and SIM.
  • In vivo studies involving rats with abdominal aortic constriction to induce pressure overload.
  • Measurements included cell surface area, protein content, systolic blood pressure, heart/body weight ratios, and left ventricular/body weight ratios.
  • Western blot analysis to assess JAK/STAT pathway activation.
  • RT-PCR analysis to evaluate angiotensinogen (AGT) mRNA expression.

Main Results:

  • SIM ameliorated CT-1-induced cardiomyocyte hypertrophy in vitro, reducing cell surface area and protein content.
  • SIM attenuated cardiac hypertrophy in vivo, as evidenced by improved hemodynamic parameters and reduced cardiac remodeling.
  • Western blot analysis revealed that the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is involved in SIM's effects.
  • RT-PCR analysis indicated that SIM's ameliorative effect may involve altered angiotensinogen (AGT) mRNA expression and subsequent changes in angiotensin II (Ang II) levels.

Conclusions:

  • Simvastatin effectively inhibits both in vitro and in vivo cardiac hypertrophy.
  • The JAK/STAT signaling pathway and the renin-angiotensin system are implicated in the cardioprotective mechanisms of SIM.
  • SIM represents a promising therapeutic agent for the prevention and treatment of cardiac hypertrophy.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...